<DOC>
	<DOCNO>NCT01188733</DOCNO>
	<brief_summary>Octreotide use control variceal bleeding . However , octreotide give vein effective less two hour . In study investigator determine whether long-acting preparation octreotide ( Sandostatin LAR ) give intra-muscular injection every month could decrease portal pressure , thus use prevent variceal bleed patient cirrhosis .</brief_summary>
	<brief_title>Efficacy Long-acting Octreotide ( Sandostatin LAR ) Reducing Portal Pressure Patients With Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Cirrhosis document biopsy , suggest characteristic feature abdominal imaging ( nodular appearance , irregular contour ) along impaired synthetic liver function thrombocytopenia Child Turcotte Pugh Class A B . 2. presence small esophageal varix , define varix &lt; 5 mm diameter , without red sign document endoscopy within 3 month enrollment 3. age â‰¥ 18 year pregnant , lactate childbearing potential practicing acceptable method birth control allergic sandostatin high risk varix endoscopy carry within 3 month assessment ( large varix red sign ) Child Turcotte Pugh Class C cirrhosis hepatocellular carcinoma evidence ongoing alcohol illicit drug abuse within 6 month study serum creatinine great 2 mg/dL platelet count 50,000 per microliter prothrombin time 4 second great control human immunodeficiency virus ( HIV ) positive symptomatic gallstone previous history upper gastrointestinal bleeding past 3 month , define hematemesis and/or melena previous history variceal bleed history congestive heart failure , unstable angina , sustain ventricular tachycardia , ventricular fibrillation use investigational drug within 1 month prior screen current use beta blocker longacting nitrate , drug therapy know influence portal pressure ( diuretic allow provided patient stable dose least 30 day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>portal hypertension</keyword>
	<keyword>varix</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>octreotide</keyword>
	<keyword>somatostatin analog</keyword>
	<keyword>Child Pugh Class A , B</keyword>
</DOC>